Following a company-wide review, Patheon will launch a new corporate strategy, exiting clinical packaging and semisolid manufacturing, optimizing the CMO network, and focusing on development services. In a press statement, Patheon’s chief executive officer, James Mullen, said, “We will create the premier, customer-focused, contract pharmaceutical development and manufacturing organization in the world. This should enable attractive earnings and cash flow to reinvest in the business a...